Browsing by Author "Papakostas, P."
Now showing items 1-18 of 18
-
Article
Adjuvant chemotherapy using CPT-11, leucovorin plus bolus 5-fluorouracil and radiotherapy in patients with rectal cancer. A feasibility study
Kalofonos, H. P.; Kardamakis, D.; Bamias, A. T.; Skarlos, Dimosthenis V.; Papakostas, P.; Bafaloukos, Dimitrios; Sakantamis, A.; Pavlidis, Nicholas; Fountzilas, George (2003)Background: The addition of CPT-11 to 5FU/leucovorin resulted in survival benefit in patients with advanced colorectal cancer suggesting that this combination could be used successfully in the adjuvant setting. We studied ...
-
Article
Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: Interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes
Pentheroudakis, George; Kotoula, V.; Roock, W. De; Kouvatseas, G.; Papakostas, P.; Makatsoris, T.; Papamichael, D.; Xanthakis, I.; Sgouros, J.; Televantou, D.; Kafiri, G.; Tsamandas, A. C.; Razi, E. D.; Galani, E.; Bafaloukos, Dimitrios; Efstratiou, I.; Bompolaki, I.; Pectasides, Dimitrios; Pavlidis, Nicholas; Tejpar, S.; Fountzilas, George (2013)Background: More than half of patients with KRAS-wild type advanced colorectal cancer (CRC) fail anti-EGFR monoclonal antibodies. We studied EGFR-axis messenger RNA (mRNA) expression and RAS, RAF, PIK3CA mutations in order ...
-
Article
DCC and TS protein expression in resected gastric cancer: A Hellenic Cooperative Oncology Group Study
Bamias, A. T.; Fountzilas, George; Michael, M. C.; Konstantaras, C.; Vrettou, E.; Eleftheriadis, E.; Papakostas, P.; Papadimitriou, K.; Pavlidis, Nicholas; Xiros, N.; Bai, M. C. (2008)There is a high risk of relapse after resection of gastric cancer. We studied the prognostic significance of the deleted colorectal cancer (DCC) gene and thymidylate synthase (TS) protein expression after resection of ...
-
Article
Docetaxel and gemcitabine combination, as first-line treatment, in patients with extensive disease small-cell lung cancer. A phase II study of the Hellenic Cooperative Oncology Group
Skarlos, Dimosthenis V.; Dimopoulos, M. A.; Kosmidis, Paraskevas A.; Papakostas, P.; Pavlidis, Nicholas; Bacoyiannis, Charalambos; Kiamouris, Ch; Klouvas, G. D.; Gogas, H.; Fountzilas, George; Samantas, E. (2003)There is some evidence that taxanes and gemcitabine are effective antitumor agents against small-cell lung cancer (SCLC). A total of 20 chemotherapy-naive patients with extensive disease (ED) SCLC, were treated as a part ...
-
Article
Dose-dense adjuvant chemotherapy with epirubicin monotherapy in patients with operable breast cancer and ≥ 10 positive axillary lymph nodes
Fountzilas, George; Nikolaides, C.; Aravantinos, Gerasimos; Skarlos, Dimosthenis V.; Kosmidis, Paraskevas A.; Papakostas, P.; Stathopoulos, G. P.; Kontostolis, E.; Bafaloukos, Dimitrios; Pavlidis, Nicholas (1998)Forty-one patients with operable breast cancer and ≥ 10 positive axillary lymph nodes were treated with 6 cycles of dose-dense adjuvant chemotherapy consisting of epirubicin (100 mg/m2) every 2 weeks with G-CSF support. A ...
-
Article
Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: First report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial
Fountzilas, George; Dafni, U.; Papadimitriou, C.; Timotheadou, E.; Gogas, H.; Eleftheraki, A. G.; Xanthakis, I.; Christodoulou, C.; Koutras, A. K.; Papandreou, C. N.; Papakostas, P.; Miliaras, S.; Markopoulos, C.; Dimitrakakis, C.; Korantzopoulos, Panagiotis; Karanikiotis, C.; Bafaloukos, Dimitrios; Kosmidis, Paraskevas A.; Samantas, E.; Varthalitis, I.; Pavlidis, Nicholas; Pectasides, Dimitrios; Dimopoulos, M. A. (2014)Background: Dose-dense sequential chemotherapy including anthracyclines and taxanes has been established in the adjuvant setting of high-risk operable breast cancer. However, the preferable taxane and optimal schedule of ...
-
Article
Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: A randomized study conducted by the hellenic cooperative oncology group
Fountzilas, George; Papadimitriou, C.; Dafni, U.; Bafaloukos, Dimitrios; Skarlos, Dimosthenis V.; Moulopoulos, L. A.; Razi, E. D.; Kalofonos, H. P.; Aravantinos, Gerasimos; Briassoulis, E. Ch; Papakostas, P.; Abela, K.; Gogas, H.; Kosmidis, Paraskevas A.; Pavlidis, Nicholas; Dimopoulos, M. A. (2001)Purpose: To compare the efficacy of two different schedules of epirubicin and paclitaxel, as first-line chemotherapy, in patients with advanced breast cancer (ABC). Patients and Methods: From October 1997 until May 1999, ...
-
Article
Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: A quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial
Pentheroudakis, George; Kalogeras, K. T.; Wirtz, R. M.; Grimani, I.; Zografos, G.; Gogas, H.; Stropp, U.; Pectasides, Dimitrios; Skarlos, Dimosthenis V.; Hennig, G.; Samantas, E.; Bafaloukos, Dimitrios; Papakostas, P.; Kalofonos, H. P.; Pavlidis, Nicholas; Fountzilas, George (2009)Background Estrogen receptor (ER) and progesterone receptor (PgR) protein expression carry weak prognostic and moderate predictive utility for the outcome of early breast cancer patients on adjuvant chemohormonotherapy. ...
-
Article
Ifosfamide plus oral etoposide salvage chemotherapy for platinum- resistant paclitaxel-pretreated ovarian cancer
Aravantinos, Gerasimos; Dimopoulos, M. A.; Kosmidis, Paraskevas A.; Bafaloukos, Dimitrios; Papadimitriou, C.; Kiamouris, Ch; Pavlidis, Nicholas; Sikiotis, K.; Papakostas, P.; Skarlos, Dimosthenis V. (2000)Background: The prognosis of platinum resistant ovarian cancer is very poor and the treatment of choice has not been clearly defined. Patients and methods: We conducted a phase II study with the combination of ifosfamide ...
-
Article
Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: A hellenic cooperative oncology group study
Briassoulis, E. Ch; Fountzilas, George; Bamias, A. T.; Dimopoulos, M. A.; Xiros, N.; Aravantinos, Gerasimos; Samantas, E.; Kalofonos, H. P.; Makatsoris, T.; Mylonakis, N.; Papakostas, P.; Skarlos, Dimosthenis V.; Varthalitis, I.; Pavlidis, Nicholas (2008)Background: Cancer of unknown primary (CUP) lacks established therapy although it affects 3% of cancer patients. We evaluated the irinotecan- oxaliplatin combination (IROX regimen) in previously untreated patients with ...
-
Article
Non-small cell lung cancer in the young: A retrospective analysis of diagnosis, management and outcome data
Mauri, D.; Pentheroudakis, George; Bafaloukos, Dimitrios; Pectasides, Dimitrios; Samantas, E.; Efstathiou, E.; Kalofonos, H. P.; Syrigos, K.; Klouvas, G. D.; Papakostas, P.; Kosmidis, Paraskevas A.; Fountzilas, George; Pavlidis, Nicholas (2006)Background: Non-small cell lung cancer (NSCLC) in young patients is uncommon and is thought to constitute a distinct oncological entity with characteristic clinicopathological patterns. Since the reported data are scant ...
-
Article
Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group
Fountzilas, George; Papakostas, P.; Dafni, U.; Makatsoris, T.; Karina, M.; Kalogera-Fountzila, Anna; Maniadakis, N.; Aravantinos, Gerasimos; Syrigos, K.; Bamias, A. T.; Christodoulou, C.; Economopoulos, T.; Kalofonos, H. P.; Nikolaou, A.; Angouridakis, N.; Stathopoulos, G. P.; Bafaloukos, Dimitrios; Pavlidis, Nicholas; Daniilidis, J. (2006)Background: The prognosis of patients with recurrent and/or metastatic head and neck cancer (HNC) is poor. Median survival of these patients following chemotherapy is in the range of 6 to 9 months. In the present randomized ...
-
Article
Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: Long-term efficacy results: A Hellenic Cooperative Oncology Group (HeCOG) study
Aravantinos, Gerasimos; Fountzilas, George; Kosmidis, Paraskevas A.; Dimopoulos, M. A.; Stathopoulos, G. P.; Pavlidis, Nicholas; Bafaloukos, Dimitrios; Papadimitriou, C.; Karpathios, S.; Georgoulias, V.; Papakostas, P.; Kalofonos, H. P.; Grimani, E.; Skarlos, Dimosthenis V. (2005)Background: We compared the combination plus Carboplatin plus paclitaxel, which is considered the treatment of choice for initial chemotherapy of advanced ovarian cancer (AOC) with a regimen combining alternating carboplatin ...
-
Article
Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: Preliminary results of a Hellenic Cooperative Ontology Group study
Skarlos, Dimosthenis V.; Aravantinos, Gerasimos; Kosmidis, Paraskevas A.; Athanasiades, A.; Stathopoulos, G. P.; Pavlidis, Nicholas; Bafaloukos, Dimitrios; Karpathios, S.; Papakostas, P.; Bamia, C.; Fountzilas, George (1997)Ninety previously untreated patients with advanced epithelial ovarian cancer (International Federation of Gynecology and Obstetrics stages IIC, III, and IV) were randomized, after initial cytoreductive surgery, to receive ...
-
Article
Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors
Pentheroudakis, George; Fountzilas, George; Kalofonos, H. P.; Golfinopoulos, Vassilis; Aravantinos, Gerasimos; Bafaloukos, Dimitrios; Papakostas, P.; Pectasides, Dimitrios; Christodoulou, C.; Syrigos, K.; Economopoulos, T.; Pavlidis, Nicholas (2008)Introduction: Cancer in the elderly is a common health issue in developed societies. We sought to present epidemiology, management and outcome data on fit elderly patients with common metastatic cancers and to identify ...
-
Article
Phase i trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: A hellenic cooperative oncology group study
Briassoulis, E. Ch; Golfinopoulos, Vassilis; Karina, M.; Papakostas, P.; Pavlidis, Nicholas; Fountzilas, George (2010)This trial aimed to define a recommended safe dose (RSD) of weekly paclitaxel and irinotecan combined with carboplatin in patients with advanced cancer. Patients with advanced cancer were eligible for this trial. Dose-limiting ...
-
Article
A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: A translational research study of the Hellenic Cooperative Oncology Group (HeCOG)
Pentheroudakis, George; Kotoula, V.; Fountzilas, E.; Kouvatseas, G.; Basdanis, G.; Xanthakis, I.; Makatsoris, T.; Charalambous, E.; Papamichael, D.; Samantas, E.; Papakostas, P.; Bafaloukos, Dimitrios; Razi, E. D.; Christodoulou, C.; Varthalitis, I.; Pavlidis, Nicholas; Fountzilas, George (2014)Background: Bevacizumab, an antibody neutralizing Vascular Endothelial Growth Factor (VEGF), is licensed for the management of patients with advanced colon cancer. However, tumor biomarkers identifying the molecular tumor ...
-
Article
Survivin and glycodelin transcriptional activity in node-positive early breast cancer: mRNA expression of two key regulators of cell survival
Kostadima, Lida; Pentheroudakis, George; Fountzilas, George; Dimopoulos, M. A.; Pectasides, Dimitrios; Gogas, H.; Christodoulou, C.; Samantas, E.; Bafaloukos, Dimitrios; Arapantoni, P.; Kalofonos, H. P.; Papakostas, P.; Economopoulos, T.; Bamias, A. T.; Pavlidis, Nicholas; Stropp, U.; Wirtz, R. M.; Hennig, G. (2006)Introduction: Glycodelin and survivin are key polypeptide regulators of cellular proliferation, apoptosis and angiogenesis. In view of contradictory reports on their functional role in tumors, we studied their transcriptional ...